GARDP 105d ago

Current developments in Clostridioides difficile prevention, therapy and R&D This REVIVE webinar was done in collaboration with the Peggy Lillis Foundation. Speakers: Benedikt Huttner, Unit Head – Research, Access, Stewardship and AMR surveillance, Department of Antimicrobial Resistance, World Health Organization (Switzerland) Paul Feuerstadt, Attending Physician, PACT Gastroenterology Center, Associate Clinical Professor of Medicine, Yale School of Medicine (USA) Kerrie Davies, Consultant Clinical Scientist, NIHR Leeds Biomedical Research Center and University of Leeds (UK) Mark Wilcox, Professor of Medical Microbiology, University of Leeds (UK) Moderator: Christian John Lillis, Chief Executive Officer, Peggy Lillis Foundation (USA) 0:00 Webinar opening words 1:30 Introduction from the moderator 07:50 Presentation 1: Global epidemiology of Clostridioides difficile and WHO priorities for prevention (Benedikt Huttner) 31:46 Presentation 2: Pathophysiology of Clostridioides difficile infection – implications for treatment (Paul Feurstadt) 51:46 Presentation 3: Updates on diagnosis (Kerrie Davies) 01:08:05 Presentation 4: Pipeline of new therapies (Mark Wilcox) 01:24:50 Questions & Answers GARDP: https://www.gardp.org/ REVIVE: https://revive.gardp.org/ Peggy Lillis Foundation: https://cdiff.org/ #webinar #GARDP #REVIVE #CDifficile #antibiotics #antibioticresistance #fecaltransplant #bacterialinfections #diagnosis #antibioticstewardship